[go: up one dir, main page]

BRPI0716749B8 - compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende - Google Patents

compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende

Info

Publication number
BRPI0716749B8
BRPI0716749B8 BRPI0716749A BRPI0716749A BRPI0716749B8 BR PI0716749 B8 BRPI0716749 B8 BR PI0716749B8 BR PI0716749 A BRPI0716749 A BR PI0716749A BR PI0716749 A BRPI0716749 A BR PI0716749A BR PI0716749 B8 BRPI0716749 B8 BR PI0716749B8
Authority
BR
Brazil
Prior art keywords
inhibitors
pyrido
pharmaceutical composition
pyrimidinone compounds
compounds
Prior art date
Application number
BRPI0716749A
Other languages
English (en)
Inventor
Bhumralkar Dilip
Cheng Hengmiao
Elizabeth Hoffman Jacqui
Tuan Tran Khanh
Ruprecht Dress Klaus
Catherine Johnson Mary
Alan Pairish Mason
Bruno Plewe Michael
David Nambu Mitchell
Thi Quy Le Phuong
Steven Kania Robert
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0716749A2 publication Critical patent/BRPI0716749A2/pt
Publication of BRPI0716749B1 publication Critical patent/BRPI0716749B1/pt
Publication of BRPI0716749B8 publication Critical patent/BRPI0716749B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

composto pirido (2,2-d) pirimidinona e seu uso como inibidores pi3. a presente invenção é direcionada a novos compostos de 4-metilpiridopirimodinona da fórmula (i), e sais dos mesmos, suas sínteses, e seus usos como inibidores de fofoinositida 3-quinase alfa (p13-k alfa).
BRPI0716749A 2006-09-15 2007-09-03 compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende BRPI0716749B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US60/845,065 2006-09-15
US94785207P 2007-07-03 2007-07-03
US60/947,852 2007-07-03
US95262807P 2007-07-30 2007-07-30
US60/952,628 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (3)

Publication Number Publication Date
BRPI0716749A2 BRPI0716749A2 (pt) 2014-02-18
BRPI0716749B1 BRPI0716749B1 (pt) 2020-10-06
BRPI0716749B8 true BRPI0716749B8 (pt) 2021-05-25

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716749A BRPI0716749B8 (pt) 2006-09-15 2007-09-03 compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende

Country Status (42)

Country Link
US (3) US7696213B2 (pt)
EP (1) EP2074122B9 (pt)
JP (1) JP4718637B2 (pt)
KR (1) KR101099926B1 (pt)
CN (1) CN101573358B (pt)
AP (1) AP2710A (pt)
AR (1) AR062785A1 (pt)
AT (1) ATE514695T1 (pt)
AU (1) AU2007297212B8 (pt)
BR (1) BRPI0716749B8 (pt)
CA (1) CA2663401C (pt)
CL (1) CL2007002682A1 (pt)
CR (1) CR10662A (pt)
CU (1) CU23783B7 (pt)
CY (1) CY1111911T1 (pt)
DK (1) DK2074122T5 (pt)
DO (1) DOP2009000039A (pt)
EA (1) EA016388B1 (pt)
ES (1) ES2366489T3 (pt)
GE (1) GEP20115306B (pt)
GT (1) GT200700077A (pt)
HK (1) HK1138589A1 (pt)
HN (1) HN2007000267A (pt)
HR (1) HRP20110621T2 (pt)
IL (1) IL197243A (pt)
MA (1) MA30709B1 (pt)
ME (1) MEP8009A (pt)
MX (1) MX2009002927A (pt)
MY (1) MY146420A (pt)
NI (1) NI200900032A (pt)
NO (1) NO342357B1 (pt)
NZ (1) NZ575167A (pt)
PE (1) PE20080670A1 (pt)
PL (1) PL2074122T3 (pt)
PT (1) PT2074122E (pt)
RS (2) RS51927B (pt)
SI (1) SI2074122T1 (pt)
TN (1) TN2009000085A1 (pt)
TW (1) TWI334353B (pt)
UY (1) UY30588A1 (pt)
WO (1) WO2008032162A1 (pt)
ZA (1) ZA200901477B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2366489T3 (es) * 2006-09-15 2011-10-20 Pfizer Products Inc. Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3.
SI2139484T1 (sl) * 2007-04-10 2013-10-30 Exelixis, Inc. Postopki za zdravljenje raka s pirido pirimidin PI3K alfa inhibitorji
CA2683820A1 (en) * 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
US20110105521A1 (en) * 2008-07-11 2011-05-05 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
JP5674661B2 (ja) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
AR072938A1 (es) 2008-08-20 2010-09-29 Southern Res Inst Derivados de piridina y pirimidina azosustituidos y su uso en el tratamiento de infecciones virales
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020238A (en) 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010039740A1 (en) * 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
NZ609448A (en) 2010-12-16 2015-07-31 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
US9675595B2 (en) 2011-08-31 2017-06-13 Novartis Ag Synergistic combinations of PI3K- and MEK-inhibitors
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
KR20170058432A (ko) 2014-10-10 2017-05-26 화이자 인코포레이티드 상승 효과적 아우리스타틴 조합
EP3302565B1 (en) 2015-06-04 2019-11-06 Pfizer Inc Solid dosage forms of palbociclib
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
ES2922898T3 (es) 2016-07-06 2022-09-21 Univ Michigan Regents Inhibidores multifuncionales de las rutas biológicas de MEK/PI3K y mTOR/MEK/PI3K y métodos terapéuticos que usan los mismos
EP3497103B1 (en) 2016-08-15 2021-05-05 Pfizer Inc. Pyridopyrimdinone cdk2/4/6 inhibitors
US11241500B2 (en) * 2016-12-14 2022-02-08 Tarveda Therapeutics, Inc. HSP90-targeting conjugates and formulations thereof
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
EA202092692A1 (ru) 2018-06-15 2021-04-21 Навитор Фармасьютикалз, Инк. Аналоги рапамицина и их применения
CA3124574A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020140053A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
CA3163680A1 (en) 2019-12-05 2021-06-10 David John O'neill Rapamycin analogs and uses thereof
CN114901664B (zh) * 2020-01-10 2024-07-02 南京再明医药有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
CA3198943A1 (en) 2020-11-18 2022-05-27 Daniel L. Flynn Gcn2 and perk kinase inhibitors and methods of use thereof
AU2022389984A1 (en) * 2021-11-18 2024-06-13 Traws Pharma, Inc. Methods and compositions for treating cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
GEP20012444B (en) 1994-11-14 2001-05-25 Warner Lambert Company Us 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
AU749750B2 (en) 1997-02-05 2002-07-04 Warner-Lambert Company Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
HUP0203803A3 (en) 2000-01-27 2004-09-28 Warner Lambert Co Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
NZ520962A (en) 2000-03-06 2003-09-26 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines cyclin-dependent tyrosine kinase inhibitors
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
EP1364950A4 (en) 2001-02-26 2005-03-09 Tanabe Seiyaku Co PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
CA2473026C (en) 2002-01-22 2011-05-03 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
ATE370952T1 (de) 2002-04-19 2007-09-15 Smithkline Beecham Corp Neue verbindungen
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
JP2007504283A (ja) 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
MXPA06000484A (es) 2003-07-11 2006-04-05 Warner Lambert Co Sal de isetionato de un inhibidor selectivo de la quinasa 4 dependiente de ciclina.
JP2006528193A (ja) 2003-07-22 2006-12-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃ−ｆｍｓキナーゼの阻害剤としてのキノリノン誘導体
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
PT1713806E (pt) 2004-02-14 2013-08-27 Irm Llc Compostos e composições como inibidores da proteína quinase
EP1718645A1 (en) 2004-02-18 2006-11-08 Warner-Lambert Company LLC 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
EP1740184A1 (en) 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
BRPI0510560A (pt) * 2004-05-04 2007-11-20 Warner Lambert Co pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
EP1761281A1 (en) 2004-06-04 2007-03-14 Pfizer Products Incorporated Method for treating abnormal cell growth
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
EP1807440B1 (en) 2004-11-03 2020-02-19 The University of Kansas Novobiocin analogues as anticancer agents
EP1828186A1 (en) 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
CA2623770C (en) * 2005-10-07 2014-05-27 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
ES2366489T3 (es) 2006-09-15 2011-10-20 Pfizer Products Inc. Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3.
AU2008224941C1 (en) * 2007-03-14 2013-06-27 Exelixis Patent Company Llc Inhibitors of the hedgehog pathway
CA2683820A1 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
WO2010039740A1 (en) 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations

Also Published As

Publication number Publication date
ES2366489T3 (es) 2011-10-20
MA30709B1 (fr) 2009-09-01
EP2074122B9 (en) 2013-09-11
TW200820972A (en) 2008-05-16
PE20080670A1 (es) 2008-06-14
AU2007297212A1 (en) 2008-03-20
TN2009000085A1 (fr) 2010-08-19
MX2009002927A (es) 2009-03-31
GEP20115306B (pt) 2011-10-10
US20100137279A1 (en) 2010-06-03
NO342357B1 (no) 2018-05-14
IL197243A (en) 2013-07-31
HN2007000267A (es) 2011-02-25
ES2366489T9 (es) 2013-12-27
CN101573358A (zh) 2009-11-04
US8273755B2 (en) 2012-09-25
CY1111911T1 (el) 2015-11-04
AP2710A (en) 2013-07-30
CU23783B7 (es) 2012-02-15
NO20091141L (no) 2009-03-31
PT2074122E (pt) 2011-08-24
KR101099926B1 (ko) 2011-12-28
CL2007002682A1 (es) 2008-04-04
US7696213B2 (en) 2010-04-13
EA200970207A1 (ru) 2009-08-28
PL2074122T3 (pl) 2011-10-31
ATE514695T1 (de) 2011-07-15
CN101573358B (zh) 2012-05-30
US20080090801A1 (en) 2008-04-17
MEP8009A (en) 2011-12-20
JP4718637B2 (ja) 2011-07-06
HRP20110621T1 (en) 2011-09-30
NZ575167A (en) 2010-10-29
NI200900032A (es) 2010-05-14
ZA200901477B (en) 2010-07-28
US20120309775A1 (en) 2012-12-06
DK2074122T5 (da) 2014-03-17
AU2007297212B8 (en) 2011-04-28
AU2007297212B2 (en) 2011-04-14
CA2663401A1 (en) 2008-03-20
AP2009004790A0 (en) 2009-04-30
WO2008032162A1 (en) 2008-03-20
CU20090040A7 (es) 2011-07-11
WO2008032162A8 (en) 2009-03-26
JP2010503653A (ja) 2010-02-04
DK2074122T3 (da) 2011-08-15
EA016388B1 (ru) 2012-04-30
GT200700077A (es) 2009-08-03
KR20090040389A (ko) 2009-04-23
RS51927B (en) 2012-02-29
MY146420A (en) 2012-08-15
EP2074122A1 (en) 2009-07-01
RS20090104A (en) 2010-06-30
BRPI0716749A2 (pt) 2014-02-18
BRPI0716749B1 (pt) 2020-10-06
HK1138589A1 (en) 2010-08-27
IL197243A0 (en) 2009-12-24
HRP20110621T2 (hr) 2013-12-06
DOP2009000039A (es) 2015-12-15
UY30588A1 (es) 2008-05-02
US8633204B2 (en) 2014-01-21
AR062785A1 (es) 2008-12-03
CA2663401C (en) 2011-07-12
SI2074122T1 (sl) 2011-10-28
TWI334353B (en) 2010-12-11
CR10662A (es) 2009-04-17
EP2074122B1 (en) 2011-06-29

Similar Documents

Publication Publication Date Title
BRPI0716749B8 (pt) compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
ECSP12012334A (es) Morfolinopirimidinas y su uso en terapia
UY32379A (es) Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones.
BR112013021638A2 (pt) "compostos inibidores de trk, seu uso e composições que os compreendem"
DOP2014000303A (es) 7H-PIRROLO[2,3-d] PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2
DOP2011000361A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cancer y otras enfermedades
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
ECSP099565A (es) Compuesto de 2-amino pirimidina
DOP2010000155A (es) Derivados de pirazol como inhibidores de 5-lo
UY32420A (es) Derivados de 6-(6-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles : preparacion, aplicacion como medicamentos y utilizacion como inhibidores de met
UY31161A1 (es) Usos de derivados de cinolina en el tratamiento de la esquizofrenia
BR112014031969A2 (pt) derivados de pirimidinona como agentes antimaláricos
ECSP24007193A (es) Compuestos pirimidínicos para usar como inhibidores de map4k1
UY32412A (es) DERIVADOS DE 4-AMINO-7,8-DIHIDROPIRIMIDO [4,3-d] PIRIMIDIN-5 (6H)-ONA
UY31289A1 (es) Nuevos derivados de la quinoliniloxipiperidina y pirrolidina, su preparacion, composiciones farmaceuticas que los contiene y sus usos en el tratamieno de enfermedades
UA95113C2 (en) Pyrido (2,3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
CU20100127A7 (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
TH151329A (th) ไพริมิดิโนนเป็นสารยับยั้ง pi3k
CU23957B1 (es) Derivados de tiazolidin-2,4-diona

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2686 DE 28-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.